Overview and Scope
Liver cancer diagnostics refers to the various methods employed to detect and diagnose liver cancer, a type of cancer that originates in the liver. It is used for the early detection and diagnosis of liver cancer via imaging and molecular testing.
Sizing and Forecast
The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.95 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to biopsy techniques and histopathology, development of biomarker detection, evolution of screening programs, advances in genetic testing, improvements in liver imaging modalities..
The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.96 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to regulatory changes and standardization, growing importance of imaging modalities, development of next-generation sequencing, expanded screening programs and awareness, rising demand for biomarker-based testing.. Major trends in the forecast period include rise in incidence and prevalence, advancements in imaging technologies, focus on non-invasive diagnostics, precision medicine and personalized diagnostics, integration of artificial intelligence (ai)..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report
Segmentation & Regional Insights
The liver cancer diagnostics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories
North America was the largest region in the liver cancer diagnostics market in 2023. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp
Major Driver Impacting Market Growth
The rising prevalence of liver cancer is expected to propel the growth of the liver cancer diagnostics market going forward. Liver cancer refers to the condition in which the liver cells grow and multiply out of control, giving rise to a life-threatening illness. Liver cancer diagnostic tests are performed to determine whether cancer cells are spreading within the liver or surrounding it after the diagnosis of primary carcinoma of the liver, so the rising prevalence of liver cancer boosts the liver cancer diagnostics market. For instance, in January 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society, a US-based voluntary health organization, the number of new cases of liver and intrahepatic bile duct cancer in females reached 13,230 in 2023, an increase from 12,640 in 2020, in the United States. Furthermore, in 2023, an estimated 41,210 new cases of liver cancer will be diagnosed in the US, where 29,380 people are expected to die. Therefore, the rising prevalence of liver cancer is driving the growth of the liver cancer diagnostic market.
Key Industry Players
Major companies operating in the liver cancer diagnostics market report are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Charles Russell Bard, Hologic Inc., Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Biocare Medical LLC, Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Bio SB Inc., Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp
The liver cancer diagnostics market report table of contents includes:
1. Executive Summary
2. Liver Cancer Diagnostics Market Characteristics
3. Liver Cancer Diagnostics Market Trends And Strategies
4. Liver Cancer Diagnostics Market – Macro Economic Scenario
5. Global Liver Cancer Diagnostics Market Size and Growth
.
.
.
31. Global Liver Cancer Diagnostics Market Competitive Benchmarking
32. Global Liver Cancer Diagnostics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Liver Cancer Diagnostics Market
34. Liver Cancer Diagnostics Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
